Tilray | TRLY - Ebitda

Stock Price
10.61
Daily Change
0.41 4.02%
Monthly
-18.95%
Yearly
631.72%
Q1 Forecast
9.94

Tilray reported $8.36M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acasti Pharma USD -3.18M 521K Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
Avita Medical AUD -21.9M 12.04M Jun/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Cronos Group USD 5.68M 3.99M Sep/2025
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.88B 1.59B Sep/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
IQVIA Holdings USD 949M 39M Sep/2025
Knight Therapeutics CAD 15.51M 3.39M Jun/2025
Moderna USD -208M 552M Sep/2025
Organigram Holdings CAD 6.15M 455K Sep/2025
Organon & Co USD 518M 4M Sep/2025
Revvity USD 248.91M 48.52M Dec/2025
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1.15B 75.8M Sep/2025
Xeris Pharmaceuticals USD 17.42M 8.83M Sep/2025